AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8682988 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 0
Study 7515260 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (10(6) KIU into the pump prime)
Number of subjects: 79
Study 7515260 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (0.5 x 10(6) KIU intravenous bolus after induction and 10(6) KIU into the pump prime)
Number of subjects: 79
Study 7515260 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline placebo
Number of subjects: 79
Study 2885022 — intervention group
Group type: EXPERIMENTAL
Intervention: Adimolol (600 mg)
Number of subjects: 8
Study 2885022 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (240 mg)
Number of subjects: 8
Study 2885022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2885022 — intervention group
Group type: EXPERIMENTAL
Intervention: Adimolol
Number of subjects: 8
Study 2885022 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 8
Study 31278429 — intervention group
Group type: EXPERIMENTAL
Intervention: 755 nm diode laser
Number of subjects: 16
Study 31278429 — intervention group
Group type: COMPARATOR
Intervention: 755 nm alexandrite laser
Number of subjects: 16
Study 28726359 — intervention group
Group type: EXPERIMENTAL
Intervention: Earplugs
Number of subjects: 63
Study 28726359 — intervention group
Group type: COMPARATOR
Intervention: No earplugs (Control)
Number of subjects: 63
Study 26204987 — intervention group
Group type: EXPERIMENTAL
Intervention: Carraguard microbicide gel
Number of subjects: 5990
Study 26204987 — intervention group
Group type: EXPERIMENTAL
Intervention: High adherence (gel used in >=85% of sex acts)
Number of subjects: 5990
Study 26204987 — intervention group
Group type: EXPERIMENTAL
Intervention: Coital frequency
Number of subjects: 5990
Study 26204987 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographic site (Western Cape vs KZN)
Number of subjects: 5990
Study 26204987 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive method
Number of subjects: 5990
Study 26204987 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner age difference
Number of subjects: 5990
Study 25277886 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein concentrate (WPC) 65 g dissolved in 500 mL water 30 minutes before lunch
Number of subjects: 45
Study 25277886 — intervention group
Group type: COMPARATOR
Intervention: Soy protein isolate (SPI) 60 g dissolved in 500 mL water 30 minutes before lunch
Number of subjects: 45
Study 23968966 — intervention group
Group type: EXPERIMENTAL
Intervention: Early recovery after surgery
Number of subjects: 101
Study 23968966 — intervention group
Group type: COMPARATOR
Intervention: Conservative regimen
Number of subjects: 101
Study 22052331 — intervention group
Group type: EXPERIMENTAL
Intervention: Wright et al./Case (Group I): (4 × Body wt (BW) (kg)) +7
Number of subjects: 99
Study 22052331 — intervention group
Group type: COMPARATOR
Intervention: Shukla et al./Control (Group II): (3 × BW (kg)) +9
Number of subjects: 99
Study 22052331 — intervention group
Group type: EXPERIMENTAL
Intervention: Wright's formula (Group I)
Number of subjects: 99
Study 20427390 — intervention group
Group type: EXPERIMENTAL
Intervention: LAL: levofloxacin (750 mg once a day), amoxicillin (1000 mg twice a day), lansoprazole (30 mg twice a day) for 7 days
Number of subjects: 432
Study 20427390 — intervention group
Group type: COMPARATOR
Intervention: CAL: clarithromycin (500 mg twice a day), amoxicillin (1000 mg twice a day), lansoprazole (30 mg twice a day) for 7 days
Number of subjects: 432
Study 20427390 — intervention group
Group type: EXPERIMENTAL
Intervention: LAL as second-line treatment
Number of subjects: 432
Study 20427390 — intervention group
Group type: COMPARATOR
Intervention: CAL as second-line treatment
Number of subjects: 432
Study 20427390 — intervention group
Group type: EXPERIMENTAL
Intervention: CAL followed by LAL
Number of subjects: 432
Study 20427390 — intervention group
Group type: COMPARATOR
Intervention: LAL followed by CAL
Number of subjects: 432
Study 20427390 — intervention group
Group type: EXPERIMENTAL
Intervention: LAL group with levofloxacin resistance
Number of subjects: 432
Study 17493978 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightweight 0.4 ounce explorer
Number of subjects: 48
Study 17493978 — intervention group
Group type: COMPARATOR
Intervention: Heavier 1.0 ounce explorer
Number of subjects: 48
Study 17493978 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison
Number of subjects: 48
Study 16170941 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind participants
Number of subjects: 12
Study 16170941 — intervention group
Group type: COMPARATOR
Intervention: Sighted participants
Number of subjects: 12
Study 16170941 — intervention group
Group type: EXPERIMENTAL
Intervention: Drivers responding to pedestrians with mobility devices
Number of subjects: 12
Study 16170941 — intervention group
Group type: COMPARATOR
Intervention: Drivers responding to pedestrians without mobility devices
Number of subjects: 12
Study 12106622 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation service in managed care organization
Number of subjects: 262
Study 12106622 — intervention group
Group type: COMPARATOR
Intervention: Usual provider-based care (Control)
Number of subjects: 262
Study 10072016 — intervention group
Group type: EXPERIMENTAL
Intervention: Propacetamol 2 g
Number of subjects: 200
Study 10072016 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac 30 mg
Number of subjects: 200
Study 8616125 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (MgSO4)
Number of subjects: 24
Study 8616125 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 24
Study 8616125 — intervention group
Group type: COMPARATOR
Intervention: Both MgSO4 and phenytoin
Number of subjects: 24
Study 1581266 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 18
Study 1581266 — intervention group
Group type: COMPARATOR
Intervention: Epidural bupivacaine
Number of subjects: 18
Study 3878717 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0
Study 3878717 — intervention group
Group type: COMPARATOR
Intervention: Methohexitone
Number of subjects: 0
Study 30877053 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 215
Study 29752179 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovaza (1.86 g of EPA and 1.5 g of DHA daily)
Number of subjects: 291
Study 29752179 — intervention group
Group type: COMPARATOR
Intervention: Control (no Lovaza)
Number of subjects: 291
Study 26051846 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound (n=32)
Number of subjects: 99
Study 26051846 — intervention group
Group type: COMPARATOR
Intervention: Phonophoresis with dexketoprofen (50 mg/session) (n=33)
Number of subjects: 99
Study 26051846 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis with dexketoprofen (50 mg/session) (n=34)
Number of subjects: 99
Study 25324251 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxemic management (PaO2=100‐150 mm Hg)
Number of subjects: 22
Study 25324251 — intervention group
Group type: COMPARATOR
Intervention: Hyperoxemic management (PaO2=200‐300 mm Hg)
Number of subjects: 22
Study 22554205 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerin 1% formulated with PLL-g-PEG
Number of subjects: 16
Study 22554205 — intervention group
Group type: COMPARATOR
Intervention: Systane Lubricant Eye Drops
Number of subjects: 16
Study 20404743 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime dosing of candesartan (with or without diuretic)
Number of subjects: 450
Study 20404743 — intervention group
Group type: COMPARATOR
Intervention: Awakening dosing of candesartan (with or without diuretic)
Number of subjects: 450
Study 20404743 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime dosing of candesartan in morning hypertension group
Number of subjects: 450
Study 20404743 — intervention group
Group type: COMPARATOR
Intervention: Awakening dosing of candesartan in morning hypertension group
Number of subjects: 450
Study 17660024 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic intra‐aortic balloon pump‐induced pulsatile perfusion during cardiopulmonary bypass (group B)
Number of subjects: 100
Study 17660024 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsatile perfusion during cardiopulmonary bypass (group A)
Number of subjects: 100
Study 16080364 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterococcus faecium (EF) M‐74 strain with 50 microg of organically bound selenium (E‐group)
Number of subjects: 0
Study 16080364 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P-group)
Number of subjects: 0
Study 12394700 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg daily for 2 weeks before surgery
Number of subjects: 70
Study 12394700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 10188901 — intervention group
Group type: EXPERIMENTAL
Intervention: D1 resection (removal of regional perigastric nodes)
Number of subjects: 400
Study 10188901 — intervention group
Group type: COMPARATOR
Intervention: D2 resection (extended lymphadenectomy to include level 1 and 2 regional nodes)
Number of subjects: 400
Study 10188901 — intervention group
Group type: EXPERIMENTAL
Intervention: D1 resection
Number of subjects: 400
Study 10188901 — intervention group
Group type: COMPARATOR
Intervention: D2 resection
Number of subjects: 400
Study 7741862 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for breast cancer (mammography)
Number of subjects: 738
Study 7741862 — intervention group
Group type: COMPARATOR
Intervention: Control cancers diagnosed before screening
Number of subjects: 738
Study 1538350 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity aerobic training
Number of subjects: 147
Study 1538350 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic training
Number of subjects: 147
Study 1538350 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexibility training
Number of subjects: 147
Study 1538350 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 147
Study 6693294 — intervention group
Group type: EXPERIMENTAL
Intervention: Six meals a day
Number of subjects: 10
Study 6693294 — intervention group
Group type: COMPARATOR
Intervention: Three meals a day
Number of subjects: 10
Study 31497674 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based decision support tools
Number of subjects: 300
Study 31497674 — intervention group
Group type: COMPARATOR
Intervention: Standard educational materials
Number of subjects: 300
Study 30577757 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate neuromuscular blockade (TOF 1-2)
Number of subjects: 60
Study 30577757 — intervention group
Group type: COMPARATOR
Intervention: Deep neuromuscular blockade (TOF 0, PTC 1-5)
Number of subjects: 60
Study 27104933 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus combined with cyclosporine A (CsA) and steroids
Number of subjects: 190
Study 27104933 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 190
Study 27104933 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 190
Study 24725237 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-450/r-ombitasvir, dasabuvir, and ribavirin for 12 weeks
Number of subjects: 380
Study 24725237 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-450/r-ombitasvir, dasabuvir, and ribavirin for 24 weeks
Number of subjects: 380
Study 24725237 — intervention group
Group type: COMPARATOR
Intervention: Historical control (telaprevir-based regimen)
Number of subjects: 380
Study 22277989 — intervention group
Group type: COMPARATOR
Intervention: MDMA (125 mg)
Number of subjects: 48
Study 22277989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 20066397 — intervention group
Group type: EXPERIMENTAL
Intervention: Unreamed intramedullary nailing
Number of subjects: 0
Study 20066397 — intervention group
Group type: COMPARATOR
Intervention: Reamed intramedullary nailing
Number of subjects: 0
Study 17299100 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal treatment program including cognitive behavioral therapy, interpersonal therapy, nutritional counseling, and supervised walking exercise (15 sessions).
Number of subjects: 96
Study 17299100 — intervention group
Group type: COMPARATOR
Intervention: Control group (obese individuals without eating disorder).
Number of subjects: 96
Study 15805342 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch (21 mg)
Number of subjects: 120
Study 15805342 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (2 and 4 mg)
Number of subjects: 120
Study 15805342 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch and gum
Number of subjects: 120
Study 15805342 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (patch, gum, placebo)
Number of subjects: 120
Study 15805342 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch therapy with cognitive-behavioral therapy
Number of subjects: 120
Study 12379050 — intervention group
Group type: EXPERIMENTAL
Intervention: Group discussion about second-hand consequences of alcohol use
Number of subjects: 184
Study 12379050 — intervention group
Group type: COMPARATOR
Intervention: Control group (completed the questionnaire only)
Number of subjects: 184
Study 9927145 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b for 12 months
Number of subjects: 130
Study 9927145 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b for 6 months
Number of subjects: 130
Study 9927145 — intervention group
Group type: COMPARATOR
Intervention: Interferon alpha-2b with detectable HCV-RNA after 1 month
Number of subjects: 130
Study 7775717 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Number of subjects: 75
Study 7775717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 2324655 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational manipulation of the cervical spine (n = 5)
Number of subjects: 9
Study 2324655 — intervention group
Group type: COMPARATOR
Intervention: Oscillatory mobilization of the cervical spine (n = 4)
Number of subjects: 9
Study 77413 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 1296
Study 77413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1296
Study 30777645 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (We Immunize Program with practical strategies training and monthly telephonic expert feedback)
Number of subjects: 62
Study 30777645 — intervention group
Group type: COMPARATOR
Intervention: Control (standard immunization update training only)
Number of subjects: 62
Study 30777645 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (We Immunize Program)
Number of subjects: 62
Study 26467301 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-containing brush-on gel (0.2% chlorhexidine digluconate) used once daily for 12 weeks
Number of subjects: 38
Study 26467301 — intervention group
Group type: COMPARATOR
Intervention: Control gel
Number of subjects: 38
Study 25899736 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic‐assisted TAP block with bupivacaine
Number of subjects: 80
Study 25899736 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic‐assisted TAP block with saline
Number of subjects: 80
Study 24139773 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month tailored physical activity intervention
Number of subjects: 266
Study 24139773 — intervention group
Group type: COMPARATOR
Intervention: wellness contact control
Number of subjects: 266
Study 21130060 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback group (BF)
Number of subjects: 20
Study 21130060 — intervention group
Group type: COMPARATOR
Intervention: Control group (CO)
Number of subjects: 20
Study 19245697 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised home exercise program established and progressed during ten home visits from a physiotherapist, with participants exercising at home up to 6 times per week for 12 months.
Number of subjects: 350
Study 19245697 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 350
Study 19245697 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised home exercise program
Number of subjects: 350
Study 16778332 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidapril 2.5 mg once daily for 6 months
Number of subjects: 30
Study 16778332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16778332 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidapril
Number of subjects: 30
Study 14759425 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylene blue (1.5 mg/Kg)
Number of subjects: 56
Study 14759425 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 56
Study 11718638 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid infiltration
Number of subjects: 48
Study 11718638 — intervention group
Group type: COMPARATOR
Intervention: Transdermal nitroglycerin (NTG) patch (5 mg for 3 days)
Number of subjects: 48
Study 9399217 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone 200 mg t.i.d.
Number of subjects: 97
Study 9399217 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone 400 mg t.i.d.
Number of subjects: 97
Study 9399217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 7584278 — intervention group
Group type: EXPERIMENTAL
Intervention: Recall of distinctive facial feature associated with a name when the occupation is also recalled.
Number of subjects: 0
Study 7584278 — intervention group
Group type: EXPERIMENTAL
Intervention: Recall of occupation associated with a name.
Number of subjects: 0
Study 7584278 — intervention group
Group type: EXPERIMENTAL
Intervention: Effects of biographical cues on recall of facial information.
Number of subjects: 0
Study 7584278 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrieval of facial information and name with biographical details.
Number of subjects: 0
Study 2824708 — intervention group
Group type: EXPERIMENTAL
Intervention: Late intensification chemotherapy (high-dose chemotherapy)
Number of subjects: 101
Study 2824708 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 101
Study 31929199 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Enamic (GE) - Polymer‐Infiltrated Ceramic Network (PICN) CAD/CAM endocrowns
Number of subjects: 20
Study 31929199 — intervention group
Group type: COMPARATOR
Intervention: Group CEREC (GC) - feldspathic ceramic CAD/CAM endocrowns
Number of subjects: 20
Study 30006361 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of the β‐blocker propranolol
Number of subjects: 60
Study 30006361 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of amisulpride
Number of subjects: 60
Study 30006361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 26541307 — intervention group
Group type: EXPERIMENTAL
Intervention: Cogmed working memory training (standard-length or shortened-length)
Number of subjects: 136
Study 26541307 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 136
Study 26179814 — intervention group
Group type: EXPERIMENTAL
Intervention: Ward-based pharmacy interventions
Number of subjects: 1094
Study 26179814 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmaceutical care (control)
Number of subjects: 1094
Study 23752285 — intervention group
Group type: EXPERIMENTAL
Intervention: Course on health and prevention of musculoskeletal injuries; Duration: 1 year; Evaluation: 3 questionnaires (beginning, 6 months, 12 months)
Number of subjects: 146
Study 23752285 — intervention group
Group type: COMPARATOR
Intervention: Control group (no course); Evaluation: 2 questionnaires (beginning, 1 year later)
Number of subjects: 146
Study 21040376 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline
Number of subjects: 9
Study 21040376 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 9
Study 18945688 — intervention group
Group type: EXPERIMENTAL
Intervention: High testosterone levels
Number of subjects: 1417
Study 18945688 — intervention group
Group type: EXPERIMENTAL
Intervention: High estradiol levels
Number of subjects: 1417
Study 18945688 — intervention group
Group type: EXPERIMENTAL
Intervention: High testosterone:17beta‐diol‐glucuronide ratio
Number of subjects: 1417
Study 16160693 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (beneficial effect group, n = 245)
Number of subjects: 303
Study 16160693 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (progressive disease group, n = 58)
Number of subjects: 303
Study 16160693 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (group with 0-1 adverse events)
Number of subjects: 303
Study 16160693 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (group with 2-5 adverse events)
Number of subjects: 303
Study 16160693 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (group with >=6 adverse events)
Number of subjects: 303
Study 12831816 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=199) with lifestyle modification and pharmacological treatments individualized by a geriatrician
Number of subjects: 400
Study 12831816 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=201) receiving usual care
Number of subjects: 400
Study 10928439 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 20
Study 10928439 — intervention group
Group type: COMPARATOR
Intervention: Control (no nimodipine)
Number of subjects: 20
Study 8880109 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonically-nebulized distilled water (UNDW) - 10 min inhalation
Number of subjects: 36
Study 8880109 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HS) - stepwise inhalation of 4.5% saline for 0.5, 1, 2, 4, and 8 min
Number of subjects: 36
Study 8880109 — intervention group
Group type: EXPERIMENTAL
Intervention: Both challenges (HS and UNDW)
Number of subjects: 36
Study 8880109 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between HS and UNDW
Number of subjects: 36
Study 8880109 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptability of HS vs UNDW
Number of subjects: 36
Study 1847408 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer Assisted Instruction (CAI) clinical simulation series
Number of subjects: 64
Study 6089858 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 40